Pharmacogenetics and cost-effectiveness analysis: a two-way street
- PMID: 21903176
- DOI: 10.1016/j.drudis.2011.08.015
Pharmacogenetics and cost-effectiveness analysis: a two-way street
Abstract
Genetic and proteomic information can be used to identify those patient groups who are most susceptible to a disease and those who are most likely to respond to particular pharmacological treatments. In this review we discuss the impact of cost-effectiveness analysis (CEA) regarding the way pharmacogenetics are adopted by healthcare systems and also, the potential impact of pharmacogenetics on the way CEA is conducted. We conclude that, although CEA can help incentivise the development of appropriate pharmacogenetic tests, when used inappropriately by payers or when ignored by developers, it can act as an obstacle to the adoption of health and efficiency improving technologies.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Comment in
-
Stratified medicine: making it happen.Drug Discov Today. 2011 Oct;16(19-20):848-9. doi: 10.1016/j.drudis.2011.09.004. Epub 2011 Sep 6. Drug Discov Today. 2011. PMID: 21920455 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical